Plasma myeloperoxidase activity as a criterion of therapeutic effectiveness for patients with cardiovascular diseases
| Autor: | Sergey N. Cherenkevich, Vadim B. Vasilyev, Valeria A. Kostevich, L. Z. Polonetsky, I. V. Buko, Alexey V. Sokolov, Daria V. Grigorieva, I. V. Gorudko, O. M. Panasenko |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
0301 basic medicine
medicine.medical_specialty Acute coronary syndrome Therapeutic effectiveness animal diseases Clinical Biochemistry 030204 cardiovascular system & hematology Biochemistry 03 medical and health sciences 0302 clinical medicine Internal medicine medicine chemistry.chemical_classification Reactive oxygen species biology Lactoferrin Myeloperoxidase activity medicine.disease 030104 developmental biology Endocrinology chemistry Myeloperoxidase Immunology biology.protein Neutrophil degranulation Molecular Medicine Ceruloplasmin |
| Zdroj: | Biochemistry (Moscow) Supplement Series B: Biomedical Chemistry. 10:173-179 |
| ISSN: | 1990-7516 1990-7508 |
| DOI: | 10.1134/s1990750816020050 |
| Popis: | A significant increase in the myeloperoxidase (MPO) activity has been found in plasma of patients with stable angina and with acute coronary syndrome (ACS) in comparison with the control group. MPO concentration was significantly increased in plasma of ACS patients. Reduced MPO activity in the treated ACS patients correlated with a favorable outcome of the disease. Generally, changes in plasma MPO concentration coincided with changes in lactoferrin concentration thus confirming the role of neutrophil degranulation in the increase of plasma concentrations of these proteins. The increase in MPO activity was obviously determined by modification of the MPO protein caused by reactive oxygen species and halogen in the molar ratio of 1: 25 and 1: 50. The decrease in plasma MPO activity may be associated with increased plasma concentrations of the physiological inhibitor of its activity, ceruloplasmin, and also with modification of the MPO protein with reactive oxygen species and halogen at their molar ratio of 1: 100 and higher. Thus, MPO activity may be used for evaluation of effectiveness of the treatment of cardiovascular diseases. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink